Xenon Pharma presents additional positive data from Phase 2b X-TOLE trial at AES 2021

Xenon Pharmaceuticals (NASDAQ:XENE) announces that additional positive data from new sub-analyses of the Phase 2b X-TOLE clinical trial will be presented at the Annual Meeting of the American Epilepsy Society (AES 2021).
On October 4, 2021, the company announced that the X-TOLE trial had met its primary efficacy endpoint in mid-stage focal epilepsy study with XEN1101 demonstrating a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency when compared to placebo (monotonic dose response; p<0.001).
Results from new sub-analyses are consistent with positive topline data and demonstrate strong efficacy across responder subgroups and increased efficacy in patients with less severe disease.
More than half of the patients in the 25 mg dose group experienced at least a 50% reduction in monthly focal seizure frequency from baseline, and, further, more than 50% of those patients experienced a 75% or greater reduction in monthly focal seizure frequency from baseline.
In those patients with less severe seizure burden at baseline (less than or equal to 8.5 seizures per month), we saw seizure freedom rates of 17.6% and 13.8% in the 20 mg and 25 mg dose groups, respectively.
Based on these results, the company believes XEN1101 has a highly competitive and differentiated clinical profile when compared to other ASMs and could play an important role in treating focal epilepsy.